Salarius announces Phase 1/2 trial of seclidemstat resumes patient enrollment

Salarius Pharmaceuticals announces that the hematologic cancer Phase 1/2 clinical trial being conducted at the University of Texas MD Anderson Cancer Center is now listed as active and recruiting on clinical trials.gov – trial NCT04734990. Salarius also announces that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide has achieved a partial response as demonstrated by at least a 30% decrease in the sum of diameters of the patient’s target lesions, bringing the objective response rate in Ewing sarcoma first-relapse patients to 60%, with a 60% disease control rate. “We are pleased that the FDA has removed the partial clinical hold on the MD Anderson trial with seclidemstat in blood cancers, and we are excited about the prospect of MD Anderson enrolling additional patients and building a broader database of patient data,” said David Arthur, president and chief executive officer of Salarius Pharmaceuticals. “MDACC researchers previously reported what we believe are encouraging interim results, and we look forward to learning what potential benefits patients will experience at higher doses of seclidemstat.”